Researchers from Children's Hospital of Philadelphia (CHOP) and Stanford University have revealed the molecular structure of TRACeR-I, a protein platform for reprogramming immune responses. A better ...

SetPoint Medical’s vagus nerve stimulator offers another treatment option for patients who do not properly respond to ...

9, 2024 — New research provides valuable insights into the brain-body immune connection identifying key communication hubs in the dural sinuses and skull bone ... Dec. 5, 2024 — Scientists ...

In recent years, researchers studying multiple sclerosis have concluded that white matter lesion volume in the brain, long ...

Discover how Treg cell dysfunction fuels inflammation in arthritis and the innovative therapies targeting this paradox for ...

Centogene NV and ROPAD consortium publish data from a landmark study identifying genetic variants that may respond to ...

The drug becomes a backup to Roche’s semorinemab (RG6100), which is licensed from AC Immune and has already ... a chance of becoming the first disease-modifying drug to be approved for the ...

AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome ACI-24.060 was generally safe and well tolerated ...

Researchers founded Rarity PBC as a public benefit corporation that will license the IP and develop operations to potentially ...

DMARDs. Disease-modifying antirheumatic drugs (DMARDs) are powerful medications that reduce inflammation and can stop PsA from getting worse. They are available as pills, can be self-injected or given ...